Vortioxetine - Lundbeck A/S

Drug Profile

Vortioxetine - Lundbeck A/S

Alternative Names: Brintellix; LU-AA21004; LuAA 21004; Trintellix

Latest Information Update: 13 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lundbeck A/S
  • Developer Lundbeck A/S; Takeda
  • Class Antidepressants; Anxiolytics; Piperazines; Small molecules; Sulfides
  • Mechanism of Action Serotonin 1A receptor agonists; Serotonin 1B receptor agonists; Serotonin 1D receptor antagonists; Serotonin 3 receptor antagonists; Serotonin 7 receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Major depressive disorder
  • Phase II Anxiety disorders
  • No development reported Generalised anxiety disorder
  • Discontinued Attention-deficit hyperactivity disorder

Most Recent Events

  • 08 Jun 2018 Launched for Major depressive disorder in China, Turkey, Hong Kong, Singapore and Argentina (PO)
  • 08 Jun 2018 Lundbeck and Takeda announces intention to submit NDA to the Ministry of Health, Labor and Welfare for Major depressive disorder in Japan
  • 02 May 2018 FDA approves an sNDA for label update of vortioxetine in Major depressive disorder in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top